Full list of GSK’s scientific presentations at ASH

Belantamab mafodotin

Abstract Name

Presenter

Presentation Details

No Evidence of BCMA Expression Loss or Systemic Immune Impairment After Treatment With the BCMA-targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

D. Lowther

Oral presentation, #248

Single-agent Belantamab Mafodotin in Patients With Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 trial

A. Nooka

Poster presentation, #3246

Efficacy and Safety of Third-line or Later (3L+) Treatments, Including the CD38 Monoclonal Antibody Class, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review

M. Hanna

Online publication

Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies

N. Boytsov

Online publication

 

Momelotinib

Abstract Name

Presenter

Presentation Details

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

A. T. Gerds

Oral presentation, #627

Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum

S. Verstovsek

Poster presentation, #3028

Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib

R. A. Mesa

Poster presentation, #1733

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 MOMENTUM study

R. A. Mesa

Poster presentation, #4351

Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib 

S. Oh

Oral presentation, #337

Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs) 

S. Verstovsek

Poster presentation, #4348

The Burden of Illness and the Incremental Burden of Transfusion Dependence in Myelofibrosis in the United States

A. T. Gerds

Poster presentation, #1729

 

Pipeline

Abstract Name

Presenter

Presentation Details

STING Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples

M. Adam

Online publication

 

Real-world outcomes

Abstract Name

Presenter

Presentation Details

Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, Spain, Italy, and Germany: Results from a Discrete Choice Experiment

R. Popat

Poster presentation, #3208

Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified by Exposure to Lenalidomide or Anti-CD38 Therapy and Double-class Refractory Status: A Retrospective Electronic Health Record Database Study

J. Richter

Poster presentation, #1891

Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study

M. Hultcrantz

Poster presentation, #4549

Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study

M. Roussel

Poster presentation, #1856

The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World 

A. Suvannasankha

Online publication

Real-world treatment patterns of patients initiating third-line therapy in relapsed or refractory multiple myeloma in Europe

M. Lehne

Online publication

 

Full list of investigator-sponsored studies and supported collaborative studies at ASH:

Belantamab mafodotin

Abstract Name

Presenter

Presentation Details

A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

E. Terpos 

Poster presentation, #1920

Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial

E. Terpos 

Poster presentation, #3234

Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma

S. Trudel

Poster presentation, #3248

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort   

J. Rubia

Poster presentation, #1881

Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-VRd Trial

V. Gonzalez-Calle

Poster presentation, #3241

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network

E. Kastritis

Poster presentation, #3244

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience

M. Hultcrantz

Poster presentation, #3225

A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

E. Terpos

Online publication

Phase 2 Study of BeLAntamab Mafodotin as Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission

A. Cohen

Online publication

 

Back to top